Starpharma deal with Dow out of the bag
Thursday, 20 January, 2005
Starpharma (ASX:SPL) was forced into a trading halt this morning after a report in Melbourne broadsheet The Age revealed that Starpharma's US subsidiary Dendritic Nanotechnologies (DNT) was about to consummate an intellectual property deal with US giant Dow Chemical company.
At time of writing, Starpharma had not yet provided the market with clarification on the deal. It reportedly involves the transfer of approximately 200 of Dow's nanotechnology patents, including patents in the dendrimer field in which Starpharma specialises. Dow was to receive an equity stake in DNT as consideration.
In November, Starpharma reported positive preliminary results from the Phase I clinical trial on its dendrimer-based vaginal microbicide Vivagel.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
